Patent intelligence · US
US 11897874
Compounds and methods for modulating Interleukin-2-inducible T-cell kinase
Compounds and methods for modulating Interleukin-2-inducible T-cell kinase
Patent details — US 11897874
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 13, 2024
- Expiration
- Feb 8, 2044
- Applicant
- Corvus Pharmaceuticals, Inc.
- Claims
- 29
- CPC classes
- A61P, A61P35/00, A61P43/00
Quick answer
US 11897874 (Compounds and methods for modulating Interleukin-2-inducible T-cell kinase) is held by Corvus Pharmaceuticals, Inc.. Status: granted. Granted Feb 13, 2024. Expires Feb 8, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Corvus Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61P, A61P35/00, A61P43/00
More from Corvus Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12351644
Anti-CD73 antibodies
granted -
US 12174192
Methods for detecting and treating cancers having adenosine pathway activation
granted -
US 12116635
Methods for detecting and treating cancers having adenosine pathway activation
granted -
US 12023337
Methods of treating cancer
granted -
US 11859007
Humanized anti-CD73 antibodies
granted -
US 11266649
Pharmaceutical formulations
granted -
US 11254686
Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
granted
Frequently asked questions
What is US patent 11897874?
US 11897874 (Compounds and methods for modulating Interleukin-2-inducible T-cell kinase) is held by Corvus Pharmaceuticals, Inc.. Status: granted. Granted Feb 13, 2024. Expires Feb 8, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11897874?
Corvus Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 11897874 expire?
Our index shows an expiration date of Feb 8, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.